BD-1047 dihydrobromide|cas:138356-21-5|西域试剂

BD-1047 dihydrobromide,99.78%

产品编号：Bellancom-16996A| CAS NO：138356-21-5| 分子式：C₁₃H₂₂Br₂Cl₂N₂| 分子量：437.04

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-16996A	￥700.00	杭州北京（现货）
Bellancom-16996A	￥900.00	杭州北京（现货）
Bellancom-16996A	￥3500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BD-1047 dihydrobromide

产品介绍

BD-1047 二氢溴酸盐是一种选择性的 sigma-1 receptor 受体拮抗剂，作用于精神分裂症动物模型，具有抗精神病活性。

生物活性

BD-1047 (dihydrobromide) is a selective functional antagonist of sigma-1 receptor, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.

体外研究

BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells.
BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

BD-1047 (dihydrobromide) (1-10 mg/kg; i.p.) decreases the Apomorphine (APO)-induced climbing behavior at the dose of 10 mg/kg in mice.
BD-1047 (dihydrobromide) counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine).
BD-1047 (dihydrobromide) reduces the increasing expression of pNR1, and reverses the Sig-1 R agonists potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Albino Swiss mice (50 days old, 25–28 g)
Dosage:	1 mg/kg, 3 mg/kg, 10 mg/kg
Administration:	Intraperitoneal injection
Result:	Decreased the APO-induced climbing at the dose of 10 mg/kg in mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Albino Swiss mice (50 days old, 25–28 g)
Dosage:	1 mg/kg, 3 mg/kg, 10 mg/kg
Administration:	Intraperitoneal injection
Result:	Decreased the APO-induced climbing at the dose of 10 mg/kg in mice.

性状

Solid

溶解性数据

In Vitro:

H₂O : 25 mg/mL (57.20 mM; Need ultrasonic)

DMSO : 25 mg/mL (57.20 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2881 mL	11.4406 mL	22.8812 mL
5 mM	0.4576 mL	2.2881 mL	4.5762 mL
10 mM	0.2288 mL	1.1441 mL	2.2881 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 33.33 mg/mL (76.26 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.72 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.72 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明